Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    jiri_mayerProf. Dr. Jiri Mayer

     

    Prof. Dr. Jiri Mayer (jmayer@fnbrno.cz), is Deputy Head of the Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic, and now also the Dean of the Medical Faculty, Masaryk University Brno, Czech Republic.  

     

    He graduated in 1985 at Brno. After training in general internal medicine during 1985-1990, he started to work at the specialized hematology dept., where he has been working up to now. His certified qualifications are internal medicine, hematology, and oncology. Since 2001, he has been a Professor at the Medical School, Masaryk´s University, Brno, Czech Republic. His scientific experience comprises:  

     

    • Internal medicine, intensive care medicine
    • Hemorheology
    • Supportive care in hematology/oncology, especially diagnostics and treatment of infection in immunocompromissed patients
    • Autologous and allogeneic bone marrow transplantation
    • Peripheral blood stem cell transplantation
    • Adult stem cell therapy
    • Diagnostic and therapy of lymphomas and leukemias (especially CML)  

     

    In 1990, he visited Cancer Research Institute in Berlin, Germany, and in 1996,  Royal Marsden Hospital, Leukaemia/Myeloma Unit, London, UK.  

     

    He is a member of European Group for Blood and Marrow Transplantation, American Society of Hematology, International Society for Experimental Hematology, European Haematology Association, and American Society for Blood and Marrow Transplantation.

     

    He is also founding member and now chairman of the CzEch Leukemia Study Group for Life, CELL (http://leukemia-cell.org).  

     

    He has been the principal investigator of many trials since 1995, in the fields of lymphomas and leukemias. He has published more than 300 papers, abstracts, and lectures.